National Bank Financial Forecasts Strong Price Appreciation for DRI Healthcare Trust (TSE:DHT.UN) Stock

DRI Healthcare Trust (TSE:DHT.UN) had its price objective raised by stock analysts at National Bank Financial from C$23.50 to C$25.50 in a research note issued on Tuesday, BayStreet reports. The firm presently has an “outperform” rating on the stock. National Bank Financial’s price objective would suggest a potential upside of 38.21% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group increased their target price on shares of DRI Healthcare Trust from C$22.25 to C$23.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Stifel Nicolaus upped their price objective on shares of DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Raymond James Financial increased their price objective on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of C$25.60.

DRI Healthcare Trust Stock Up 4.1%

Shares of DRI Healthcare Trust stock traded up C$0.73 during mid-day trading on Tuesday, hitting C$18.45. The stock had a trading volume of 77,329 shares, compared to its average volume of 56,188. The firm has a 50-day moving average of C$17.61 and a two-hundred day moving average of C$17.35. DRI Healthcare Trust has a 12-month low of C$14.10 and a 12-month high of C$19.75. The firm has a market cap of C$1.02 billion, a P/E ratio of -23.06 and a beta of 0.37.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.